CD10蛋白在结直肠癌组织中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2020.05.003

摘要/Abstract

摘要： 目的：研究CD10蛋白在结直肠癌组织中的表达及其与结直肠癌的各临床病理指标之间的关系，探讨其在结直肠癌发生、发展中的作用。方法：收集78例结直肠癌组织标本及22例癌旁正常组织样本，运用免疫组化EliVision法检测CD10蛋白的表达，并采用卡方检验分析其表达强度及分布比例与结直肠癌临床病理指标的关系。结果：CD10蛋白在结直肠癌组织和正常结肠黏膜组织中的阳性表达率分别为46.2%（36/78）和0，差异有统计学意义（P < 0.01）。结直肠癌组织中CD10蛋白表达比例与各临床病理指标均无明显相关（P > 0.05）。结直肠癌组织中CD10蛋白表达强度与患者性别、年龄、肿瘤部位、分化程度、浸润深度无明显相关（P > 0.05），而与肿瘤的临床分期、有无脉管侵犯及淋巴结转移有关（P < 0.05），中晚期结直肠癌CD10蛋白表达强度高于早期肿瘤（P=0.033），周围淋巴结转移阳性的结直肠癌CD10蛋白表达强度高于淋巴结阴性病例（P=0.023），存在脉管受侵犯的结直肠癌CD10蛋白表达强度高于无脉管受侵病例（P=0.004）。结论：CD10蛋白在结直肠癌组织中呈高表达，且表达强度与肿瘤的临床分期、有无脉管侵犯及淋巴结转移有关，可能有促进结直肠癌发展和浸润转移的作用。

关键词: 结直肠癌, CD10, 中性肽链内切酶, 免疫组织化学

Abstract: OBJECTIVE: The aim of this study was to investigate associations between expression of CD10 protein and clinicopathological characteristics in colorectal cancer patients. METHODS: 78 cases of colorectal cancer tissue samples and 22 cases of neighboring noncancer colorectal tissue samples were collected from colorectal cancer patients. In addition,expression of CD10 protein in tissue samples was determined using rapid immunohistochemical EliVision method. Relationships between the expression intensity and clinicopathological characteristics of colorectal cancer were analyzed by the Chi Square test. RESULTS: There was no expression of CD10 protein in 22 normal colorectal tissue samples. The positive rate of CD10 expression was significantly different in colorectal cancer tissue samples and in neighboring noncancer colorectal tissue samples:46.2%(36/78) and 0,(P < 0.01). The expression intensity of CD10 protein in cancer tissues was not clearly related to gender,age,tumor location,differentiation degree and depth of invasion (P > 0.05) but was higher in the more advanced stages than in the early stages (P=0.033),and was also associated with lymph node metastasis (P=0.023) and vessel invasion (P=0.004). On the other hand,the data show no significant correlation between the expression ratio of CD10 protein and clinicopathological characteristics of colorectal cancer (P > 0.05). CONCLUSION: CD10 protein was highly expressed in colorectal cancer tissues and the expression intensity was associated with clinical stage,lymph node metastasis and vessel invasion,which suggests that CD10 protein may play roles in promoting the development,invasion and metastasis of colorectal cancer.

Key words: colorectal cancer, CD10, neutral endopeptidase, immunohistochemistry

中图分类号:

R735.3+4

杨修远, 潘月龙. CD10蛋白在结直肠癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 344-349.

YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.

参考文献

[1] MAGUER-SATTA V, BESANÇON R, BACHELARD-CASCALES E. Concise review:neutral endopeptidase (CD10):a multifaceted environment actor in stem cells, physiological mechanisms, and cancer[J]. Stem Cells, 2011, 29(3):389-396.
[2] IWAYA K, OGAWA H, IZUMI M, et al. Stromal expression of CD10 in invasive breast carcinoma:a new predictor of clinical outcome[J]. Virchows Arch, 2002, 440(6):589-593.
[3] SASAKI T, KUNIYASU H, LUO Y, et al. Serum CD10 is associated with liver metastasis in colorectal cancer[J]. J Surg Res, 2014, 192(2):390-394.
[4] BERNESCU I, REICHSTEIN A C, LUCHTEFELD M, et al. Does CD10 expression predict lymph node metastasis in colorectal cancer?[J]. Dis Colon Rectum, 2016, 59(1):22-27.
[5] JEMAL A, CENTER M M, DESANTIS C, et al. Global patterns of cancer incidence and mortality rates and trends[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(8):1893-1907.
[6] 中国疾病预防控制中心慢性非传染性疾病预防控制中心, 国家卫生计生委统计信息中心. 中国死因监测数据集(2014)[M]. 北京:科学普及出版社, 2015:58.
[7] 刘芸, 廖晓龙. CD10分子的研究进展及临床应用[J]. 国际免疫学杂志, 2014, 37(5):363-366.
[8] KIM J H, HWANG S E, YU H C, et al. Distribution of CD10-positive epithelial and mesenchymal cells in human mid-term fetuses:a comparison with CD34 expression[J]. Anat Cell Biol, 2014, 47(1):28-39.
[9] KELLER P J, ARENDT L M, SKIBINSKI A, et al. Defining the cellular precursors to human breast cancer[J]. PNAS, 2012, 109(8):2772-2777.
[10] JANA S H, JHA B M, PATEL C, et al. CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis[J]. Indian J Pathol Microbiol, 2014, 57(4):530-536.
[11] 黄雯, 孟刚, 陈青. 乳腺癌中OPN、CD44v6及CD10的表达及其临床意义[J]. 临床与实验病理学杂志, 2016, 32(1):23-28.
[12] IKENAGA N, OHUCHIDA K, MIZUMOTO K, et al. CD10+pancreatic stellate cells enhance the progression of pancreatic cancer[J]. Gastroenterology, 2010, 139(3):1041-1051.
[13] OGAWA H, IWAYA K, IZUMI M, et al. Expression of CD10 by stromal cells during colorectal tumor development[J]. Hum Pathol, 2002, 33(8):806-811.
[14] YAO T, TAKATA M, TUSTSUMI S, et al. Phenotypic expression of gastrointestinal differentiation markers in colorectal adenocarcinomas with liver metastasis[J]. Pathology, 2002, 34(6):556-560.
[15] FUJITA S, TANIGUCHI H, YAO T, et al. Multi-institutional study of risk factors of liver metastasis from colorectal cancer:correlation with CD10 expression[J]. Int J Colorectal Dis, 2010, 25(6):681-686.
[16] OHJI Y, YAO T, EGUCHI T, et al. Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression:Multivariate analysis of clinicopathological and immuno-histochemical factors[J/OL]. Oncol Rep, 2007. DOI:10.3892/or.17.3.525.
[17] RAPOSO T P, COMES M S, IDOWU A, et al. CD10 inhibits cell motility but expression is associated with advanced stage disease in colorectal cancer[J]. Exp Mol Pathol, 2018, 104(3):190-198.
[18] KUNIYASU H, LUO Y, FUJⅡ K, et al. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver[J]. Gut, 2010, 59(3):348-356.
[19] HIRANO K, NIMURA S, MIZOGUCHI M, et al. Early colorectal carcinomas:CD10 expression, mucin phenotype and submucosal invasion[J]. Pathol Int, 2012, 62(9):600-611.
[20] NISHIDA T, EGASHIRA Y, AKUTAGAWA H, et al. Predictors of lymph node metastasis in T1 colorectal carcinoma:an immunophenotypic analysis of 265 patients[J]. Dis Colon Rectum, 2014, 57(8):905-915.